



# Marksans Pharma Ltd.

15<sup>th</sup> December, 2022

To,  
**BSE Limited**  
Corporate Relation Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001  
**Scrip Code: 524404**

**National Stock Exchange of India Limited**  
Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai -400051  
**Symbol: MARKSANS**

**Ref.: Buyback of equity shares of Re. 1 each of Marksans Pharma Limited (“Company”) in terms of Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 (“SEBI Buyback Regulations”) through open market using the Stock Exchanges Mechanism (“Buyback”)**

**Sub.: Extinguishment of Equity Shares pursuant to Buyback**

Dear Sir,

With reference to the captioned matter and pursuant to SEBI Buyback Regulations, the following are the details of the further Equity Shares bought back by the Company, during the period, starting from November 01, 2022 to November 30, 2022, (settlement done till November 29, 2022) which were extinguished on December 9, 2022:

<b>Reconciliation of Equity Share Capital of the Company (Pre and Post extinguishment)</b>		
<b>Particulars</b>	<b>No. of Equity Shares</b>	<b>Equity Share Capital (Rs.)</b>
Paid-up Equity Share Capital (Pre-extinguishment) <sup>(1)</sup> (A)	40, 30,74,114	40, 30,74,114
Equity Shares extinguished on December 9, 2022 (B)	40,000	40,000
Paid-up Equity Share Capital (Post-extinguishment) <sup>(2)</sup> (A-B)	40,30,34,114	40,30,34,114

Notes:

(1) Paid-up Equity Share Capital of the Company prior to the current extinguishment.

(2) Paid-up Equity Share Capital of the Company after the extinguishment on December 9, 2022.

We confirm that the equity shares of the Company were extinguished in compliance with SEBI Buyback Regulations.

Accordingly, the Paid-up Equity Share Capital of the Company has come down from 40, 30,74,114 Equity Shares of Re. 1 each face value to 40,30,34,114 Equity Shares of Re. 1 each face value with effect from December 9, 2022.

CIN : L24110MH1992PLC066364

[www.marksanspharma.com](http://www.marksanspharma.com)

**Marksans Pharma Ltd.**

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011  
E-mail: [info@marksanspharma.com](mailto:info@marksanspharma.com)



# Marksans Pharma Ltd.

We enclose herewith debit confirmation letter received from National Securities Depository Limited dated December 9, 2022 and E-mail confirmation dated December 14, 2022 received from Central Depository Services (India) Limited to the above effect for your reference and records.

Kindly take the above on record.

Thanking you,

Yours Faithfully  
For **Marksans Pharma Limited**

**Harshavardhan Panigrahi**  
Company Secretary

Encl: As above

Ref: II/CA/COM/73138/2022

December 09, 2022

Mr. Harshvardhan Panigrahi  
Company Secretary  
Marksans Pharma Limited  
601-622, 6th Floor, Chintamani Plaza  
Mohan Studio Compound  
Andheri-Kurla Road, Andheri (E)  
Mumbai - 400099

**Sub : Buy-back (open market purchase)**

Dear Sir,

As per the corporate action(s) executed by your R&T Agent/Registry Division viz; Bigshare Services Pvt. Limited, Equity Shares were credited/debited to the account(s) in the NSDL system, details of which are given below :

<i>ISIN</i>	<i>ISIN Description</i>	<i>D/C</i>	<i>Records</i>	<i>Quantity</i>	<i>Execution Date</i>
INE750C01026	MARKSANS PHARMA LTD. EQ NEW RE.1/ -	Debit	1	40,000.000	09/Dec/2022

You may contact your R&T Agent/ Registry Division for further details in this regard.

Yours faithfully,

**Rakesh Mehta**  
**Vice President**

**harshavardhan@marksanspharma.com**

---

**From:** Akash Bharti /OPS/L PAREL <akashb@cdslindia.com>  
**Sent:** 15 December 2022 11:08  
**To:** 'Karan'; Arul  
**Cc:** 'Jibu John'; Arzaan Tarapore /OPS/L PAREL; harshavardhan@marksanspharma.com; Deborshi Choudhury /BD/L PAREL; Karan Dudhwadkar /OPS/L PAREL  
**Subject:** [SPAM] RE: INE750C01026\_Marksans Pharma Ltd-BUY BACK-CA DOCS-CAPITAL UPDATION

Dear Sir,

Since your electronic corporate action was done in NSDL and only capital updation part was in CDSL, hence you are requested to consider our trailing mail for submission to exchange.

Regards,

**Sachin Kalsulkar**

Dy. Manager – Operations

Central Depository Services (India) Ltd.

---

**From:** Akash Bharti /OPS/L PAREL **On Behalf Of** CA IPO

**Sent:** 14-Dec-2022 18:17

**To:** 'Arul' <bssca@bigshareonline.com>; Karan Dudhwadkar /OPS/L PAREL <karand@cdslindia.com>; Arzaan Tarapore /OPS/L PAREL <ArzaanT@cdslindia.com>

**Cc:** 'Jibu John' <jibu@bigshareonline.com>; 'Karan' <companysecretary@marksanspharma.com>; harshavardhan@marksanspharma.com; Deborshi Choudhury /BD/L PAREL <deborshic@cdslindia.com>

**Subject:** RE: INE750C01026\_Marksans Pharma Ltd-BUY BACK-CA DOCS-CAPITAL UPDATION

Dear Sir,

With reference to your trailing mail on captioned subject.

Please note that as per your request we have initiated successfully the physical corporate action of "BUYBACK" for ISIN no. **INE750C01026 (MARKSANS PHARMA LIMITED)** and as per our record the existing Issued and Listed Capital of company in CDSL record is **Rs.40,30,34,114.00**.

This is for your information.

Regards,

**Sachin Kalsulkar**

Dy. Manager – Operations

Central Depository Services (India) Ltd.

---

**From:** Arul <bssca@bigshareonline.com>

**Sent:** 14-Dec-2022 15:40

**To:** CA IPO <caipo@cdslindia.com>; Karan Dudhwadkar /OPS/L PAREL <karand@cdslindia.com>; Arzaan Tarapore /OPS/L PAREL <ArzaanT@cdslindia.com>